Vaccination Against SARS-CoV-2 and Mortality in Hemodialysis Patients: Three is Good

Demet Yavuz; Düriye Sıla Karagöz Özen; Eşe Başbulut; Melek Bilgin; Mehmet Derya Demirag

Makale detayları

Vaccination Against SARS-CoV-2 and Mortality in Hemodialysis Patients: Three is Good

Yazarlar:

Demet Yavuz | Düriye Sıla Karagöz Özen | Eşe Başbulut | Melek Bilgin | Mehmet Derya Demirag

Yayıncı:

Karyay Karadeniz Yayımcılık

Ana Başlıklar:

İç Hastalıkları

Dergi:

Black Sea Journal of Health Science Vol.6 Issue 3, pp.398-403

Belge Tipi:

Makale

Yayın Tarihi:

1/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001292681

pISSN:

2619-9041

Anahtar kelimeler:

Özet:

 This study has investigated the vaccination rates against SARS-CoV-2 infection, antibody response to vaccine types, and factors affecting mortality in maintenance hemodialysis patients.98 of 143 patients undergoing hemodialysis in our clinic had 3 doses of BNT162b2 Pfizer-BioNTechh or CoronaVac Sinovac Life Sciences vaccine. Of these 98 patients, blood samples were obtained from 52 patients who agreed to obtain serum samples before and after vaccination. The serum samples were analyzed using the Abbott SARS-CoV-2 immunoassay designed to detect IgG antibodies against the receptor-binding domain of the S1 subunit of the spike protein of SARS-CoV-2. The rate of vaccination with at least one dose of vaccine was 85.3, and the frequency of SARS-CoV-2 infection was 58.7. The patients whose antibody titer was obtained after the third dose of vaccine n52 were divided into two groups according to the last vaccine type, as BioNTechh group of 16 patients and the Sinovac group of 36 patients. Considering all 52 patients with 3 doses of vaccine, the median antibody level was 397.3 min-max 4.5-40000 before the third vaccine dose, while 1325.3 min-max 10.5-40000 after the third vaccine dose P0.001. In patients with the last vaccine dose of Sinovac n36, the median antibody titer was 168.2 min-max 4.5-40000 before the third vaccine dose, while 851.7 min-max 55.2-40.000 after the third vaccine dose P0.01. In patients with the last vaccine dose of BioNTechh, the median antibody titer was 2738.6 min-max 9.4-37723.4 before the third vaccine dose, while 37575.8 min-max 10.5-40000 after the third vaccine dose P0.002. The frequency of SARS-CoV-2 infection P0.001 and SARS-CoV-2 infection-related mortality rates were significantly lower in vaccinated patients than in unvaccinated patients P0.001. SARS-CoV-2 vaccine doses elicited a high seropositive response in patients receiving maintenance dialysis. Those who received the last 3rd dose of vaccine with BNT162b2 had higher antibody levels than those with CoronaVacSinovac. In addition, regardless of the vaccine type, being vaccinated with any of them decreased the incidence of SARS-CoV-2 infection and the mortality rate.

 This study has investigated the vaccination rates against SARS-CoV-2 infection, antibody response to vaccine types, and factors affecting mortality in maintenance hemodialysis patients.98 of 143 patients undergoing hemodialysis in our clinic had 3 doses of BNT162b2 Pfizer-BioNTechh or CoronaVac Sinovac Life Sciences vaccine. Of these 98 patients, blood samples were obtained from 52 patients who agreed to obtain serum samples before and after vaccination. The serum samples were analyzed using the Abbott SARS-CoV-2 immunoassay designed to detect IgG antibodies against the receptor-binding domain of the S1 subunit of the spike protein of SARS-CoV-2. The rate of vaccination with at least one dose of vaccine was 85.3, and the frequency of SARS-CoV-2 infection was 58.7. The patients whose antibody titer was obtained after the third dose of vaccine n52 were divided into two groups according to the last vaccine type, as BioNTechh group of 16 patients and the Sinovac group of 36 patients. Considering all 52 patients with 3 doses of vaccine, the median antibody level was 397.3 min-max 4.5-40000 before the third vaccine dose, while 1325.3 min-max 10.5-40000 after the third vaccine dose P0.001. In patients with the last vaccine dose of Sinovac n36, the median antibody titer was 168.2 min-max 4.5-40000 before the third vaccine dose, while 851.7 min-max 55.2-40.000 after the third vaccine dose P0.01. In patients with the last vaccine dose of BioNTechh, the median antibody titer was 2738.6 min-max 9.4-37723.4 before the third vaccine dose, while 37575.8 min-max 10.5-40000 after the third vaccine dose P0.002. The frequency of SARS-CoV-2 infection P0.001 and SARS-CoV-2 infection-related mortality rates were significantly lower in vaccinated patients than in unvaccinated patients P0.001. SARS-CoV-2 vaccine doses elicited a high seropositive response in patients receiving maintenance dialysis. Those who received the last 3rd dose of vaccine with BNT162b2 had higher antibody levels than those with CoronaVacSinovac. In addition, regardless of the vaccine type, being vaccinated with any of them decreased the incidence of SARS-CoV-2 infection and the mortality rate.

 This study has investigated the vaccination rates against SARS-CoV-2 infection, antibody response to vaccine types, and factors affecting mortality in maintenance hemodialysis patients.98 of 143 patients undergoing hemodialysis in our clinic had 3 doses of BNT162b2 Pfizer-BioNTechh or CoronaVac Sinovac Life Sciences vaccine. Of these 98 patients, blood samples were obtained from 52 patients who agreed to obtain serum samples before and after vaccination. The serum samples were analyzed using the Abbott SARS-CoV-2 immunoassay designed to detect IgG antibodies against the receptor-binding domain of the S1 subunit of the spike protein of SARS-CoV-2. The rate of vaccination with at least one dose of vaccine was 85.3, and the frequency of SARS-CoV-2 infection was 58.7. The patients whose antibody titer was obtained after the third dose of vaccine n52 were divided into two groups according to the last vaccine type, as BioNTechh group of 16 patients and the Sinovac group of 36 patients. Considering all 52 patients with 3 doses of vaccine, the median antibody level was 397.3 min-max 4.5-40000 before the third vaccine dose, while 1325.3 min-max 10.5-40000 after the third vaccine dose P0.001. In patients with the last vaccine dose of Sinovac n36, the median antibody titer was 168.2 min-max 4.5-40000 before the third vaccine dose, while 851.7 min-max 55.2-40.000 after the third vaccine dose P0.01. In patients with the last vaccine dose of BioNTechh, the median antibody titer was 2738.6 min-max 9.4-37723.4 before the third vaccine dose, while 37575.8 min-max 10.5-40000 after the third vaccine dose P0.002. The frequency of SARS-CoV-2 infection P0.001 and SARS-CoV-2 infection-related mortality rates were significantly lower in vaccinated patients than in unvaccinated patients P0.001. SARS-CoV-2 vaccine doses elicited a high seropositive response in patients receiving maintenance dialysis. Those who received the last 3rd dose of vaccine with BNT162b2 had higher antibody levels than those with CoronaVacSinovac. In addition, regardless of the vaccine type, being vaccinated with any of them decreased the incidence of SARS-CoV-2 infection and the mortality rate.

 This study has investigated the vaccination rates against SARS-CoV-2 infection, antibody response to vaccine types, and factors affecting mortality in maintenance hemodialysis patients.98 of 143 patients undergoing hemodialysis in our clinic had 3 doses of BNT162b2 Pfizer-BioNTechh or CoronaVac Sinovac Life Sciences vaccine. Of these 98 patients, blood samples were obtained from 52 patients who agreed to obtain serum samples before and after vaccination. The serum samples were analyzed using the Abbott SARS-CoV-2 immunoassay designed to detect IgG antibodies against the receptor-binding domain of the S1 subunit of the spike protein of SARS-CoV-2. The rate of vaccination with at least one dose of vaccine was 85.3, and the frequency of SARS-CoV-2 infection was 58.7. The patients whose antibody titer was obtained after the third dose of vaccine n52 were divided into two groups according to the last vaccine type, as BioNTechh group of 16 patients and the Sinovac group of 36 patients. Considering all 52 patients with 3 doses of vaccine, the median antibody level was 397.3 min-max 4.5-40000 before the third vaccine dose, while 1325.3 min-max 10.5-40000 after the third vaccine dose P0.001. In patients with the last vaccine dose of Sinovac n36, the median antibody titer was 168.2 min-max 4.5-40000 before the third vaccine dose, while 851.7 min-max 55.2-40.000 after the third vaccine dose P0.01. In patients with the last vaccine dose of BioNTechh, the median antibody titer was 2738.6 min-max 9.4-37723.4 before the third vaccine dose, while 37575.8 min-max 10.5-40000 after the third vaccine dose P0.002. The frequency of SARS-CoV-2 infection P0.001 and SARS-CoV-2 infection-related mortality rates were significantly lower in vaccinated patients than in unvaccinated patients P0.001. SARS-CoV-2 vaccine doses elicited a high seropositive response in patients receiving maintenance dialysis. Those who received the last 3rd dose of vaccine with BNT162b2 had higher antibody levels than those with CoronaVacSinovac. In addition, regardless of the vaccine type, being vaccinated with any of them decreased the incidence of SARS-CoV-2 infection and the mortality rate.

Makale detayları

Vaccination Against SARS-CoV-2 and Mortality in Hemodialysis Patients: Three is Good

Yazarlar:

Demet Yavuz | Düriye Sıla Karagöz Özen | Eşe Başbulut | Melek Bilgin | Mehmet Derya Demirag

Yayıncı:

Karyay Karadeniz Yayımcılık

Ana Başlıklar:

İç Hastalıkları

Dergi:

Black Sea Journal of Health Science Vol.6 Issue 3, pp.398-403

Belge Tipi:

Makale

Yayın Tarihi:

1/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001292681

pISSN:

2619-9041

COVID-19 vaccination

SARS-CoV-2

Maintenance hemodialysis

MortalityCOVID-19 vaccination

SARS-CoV-2

Maintenance hemodialysis

Mortality

Sayı

Makale detayları

Yazarlar: Demet Yavuz | Düriye Sıla Karagöz Özen | Eşe Başbulut | Melek Bilgin | Mehmet Derya Demirag

Yayıncı: Karyay Karadeniz Yayımcılık

Ana Başlıklar: İç Hastalıkları

Dergi: Black Sea Journal of Health Science Vol.6 Issue 3, pp.398-403

Belge Tipi: Makale

Yayın Tarihi: 1/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001292681

pISSN: 2619-9041

Sayı

Yazarlar:

Demet Yavuz | Düriye Sıla Karagöz Özen | Eşe Başbulut | Melek Bilgin | Mehmet Derya Demirag

Yayıncı:

Karyay Karadeniz Yayımcılık

Ana Başlıklar:

İç Hastalıkları

Dergi:

Black Sea Journal of Health Science Vol.6 Issue 3, pp.398-403

Belge Tipi:

Makale

Yayın Tarihi:

1/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001292681

pISSN:

2619-9041